Episode
Episode 181 - Pete Smith - Co-Founder, CEO & President of Remix Therapeutics
- Podcast
- The BioHub - by Avetix
- Published
- May 27, 2026
- Duration seconds
- 1666
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-181-pete-smith-co-founder-ceo-president-of-remix-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-181-pete-smith-co-founder-ceo-president-of-remix-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Today on the podcast, we’re joined by Peter Smith, co-founder and CEO of — a company pioneering a new frontier in RNA-processing therapeutics. Peter has spent more than two decades at the forefront of oncology and drug discovery, with leadership roles spanning Takeda, Millennium Pharmaceuticals, and H3 Biomedicine before launching Remix to tackle diseases through precision RNA modulation. Remix is working to transform patient's lives through modulation of RNA processing and addressing drug targets in diseases of high unmet medical need. They're a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).